Skip to content
10-K

Annual Report

DRUGS MADE IN AMERICA ACQUISITION II CORP. DMII DMIIR DMIIU

0001213900-26-044055

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 15, 2026 63.7M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.02M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$194.3K
Cash And Equivalents FY 2025 · Dec 31, 2025 $223
Stockholders Equity FY 2025 · Dec 31, 2025 −$17.77M
Stockholders Equity FY 2025 · Dec 31, 2024 −$116.72K
Current Liabilities FY 2025 · Dec 31, 2025 $300.86K
Current Liabilities FY 2025 · Dec 31, 2024 $254.78K
Total Liabilities FY 2025 · Dec 31, 2025 $17.8M
Total Liabilities FY 2025 · Dec 31, 2024 $254.78K
Current Assets FY 2025 · Dec 31, 2025 $26.04K
Current Assets FY 2025 · Dec 31, 2024 $59.62K
Total Assets FY 2025 · Dec 31, 2025 $504.96M
Total Assets FY 2025 · Dec 31, 2024 $138.06K
Sga Expense FY 2025 · Dec 31, 2025 $488.39K
Sga Expense FY 2025 · Dec 31, 2024 $151.72K
Net Income FY 2025 · Dec 31, 2025 $4.19M
Net Income FY 2025 · Dec 31, 2024 −$151.72K
Operating Income FY 2025 · Dec 31, 2025 −$488.39K
Operating Income FY 2025 · Dec 31, 2024 −$151.72K